ArticleBiometrics2020
Statistical inference for net benefit measures in biomarker validation studies.
Article in Biometrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Number Needed to Test in Diagnostic Comparative Effectiveness Research: Implications for Evaluating the Utility and Value of Artificial Intelligence.Korean journal of radiology · 2026Article
- Are polygenic scores for psychiatric and substance use outcomes "ready" for clinical application? Current state and next steps.Psychiatric genetics · 2026Review
- Online validation of DC/TMD Axis II questionnaires for assessing temporomandibular disorders.Journal of oral & facial pain and headache · 2026Article
- Weighted Brier Score - an Overall Summary Measure for Risk Prediction Models with Clinical Utility Consideration.Statistics in biosciences · 2025Article
- Extended sample size calculations for evaluation of prediction models using a threshold for classification.BMC medical research methodology · 2025Article
- Expected Value of Sample Information Calculations for Risk Prediction Model Validation.Medical decision making : an international journal of the Society for Medical Decision Making · 2025Article
- Bayesian Decision Curve Analysis With Bayesdca.Statistics in medicine · 2024Article
- Article
- Evaluation of clinical prediction models (part 3): calculating the sample size required for an external validation study.BMJ (Clinical research ed.) · 2024Article
- Constructing time-invariant dynamic surveillance rules for optimal monitoring schedules.Biometrics · 2023Article
- Closed-Form Solution of the Unit Normal Loss Integral in 2 Dimensions, with Application in Value-of-Information Analysis.Medical decision making : an international journal of the Society for Medical Decision Making · 2023Article
- Value-of-Information Analysis for External Validation of Risk Prediction Models.Medical decision making : an international journal of the Society for Medical Decision Making · 2023Article
- Decision curve analysis: confidence intervals and hypothesis testing for net benefit.Diagnostic and prognostic research · 2023Article
- Bayesian Statistics for Medical Devices: Progress Since 2010.Therapeutic innovation & regulatory science · 2023Review
- Multiparametric Quantitative Imaging Biomarkers for Phenotype Classification: A Framework for Development and Validation.Academic radiology · 2023Review
- Targeted Search for Individualized Clinical Decision Rules to Optimize Clinical Outcomes.Statistics in biosciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Referral strategies based on risk scores and medical tests are commonly proposed. Direct assessment of their clinical utility requires implementing the strategy and is not possible in the early phases of biomarker research. Prior to late-phase studies, net benefit measures can be used to assess the potential clinical impact of a proposed strategy. Validation studies, in which the biomarker defines a prespecified referral strategy, are a gold standard approach to evaluating biomarker potential. Uncertainty, quantified by a confidence interval, is important to consider when deciding whether a biomarker warrants an impact study, does not demonstrate clinical potential, or that more data are needed. We establish distribution theory for empirical estimators of net benefit and propose empirical estimators of variance. The primary results are for the most commonly employed estimators of net benefit: from cohort and unmatched case-control samples, and for point estimates and net benefit curves. Novel estimators of net benefit under stratified two-phase and categorically matched case-control sampling are proposed and distribution theory developed. Results for common variants of net benefit and for estimation from right-censored outcomes are also presented. We motivate and demonstrate the methodology with examples from lung cancer research and highlight its application to study design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.